标题
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
作者
关键词
-
出版物
PLoS One
Volume 11, Issue 2, Pages e0149099
出版商
Public Library of Science (PLoS)
发表日期
2016-02-17
DOI
10.1371/journal.pone.0149099
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers
- (2012) Anurag Singh et al. CELL
- The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
- (2012) Madhu S. Kumar et al. CELL
- Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
- (2012) Michael Steckel et al. CELL RESEARCH
- MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
- (2012) Dai Horiuchi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
- (2012) Andrew V. Biankin et al. NATURE
- Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma
- (2012) C. K. Cheng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetic Interactions in Cancer Progression and Treatment
- (2011) Alan Ashworth et al. CELL
- Cdc2: a monopotent or pluripotent CDK?
- (2011) X. Hu et al. CELL PROLIFERATION
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Functional Viability Profiles of Breast Cancer
- (2011) R. Brough et al. Cancer Discovery
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Cdc25 Phosphatases Are Required for Timely Assembly of CDK1-Cyclin B at the G2/M Transition
- (2010) Oleg Timofeev et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical Relevance of KRAS in Human Cancers
- (2010) Sylwia Jančík et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells
- (2010) Y Wang et al. ONCOGENE
- An overview of Cdk1-controlled targets and processes
- (2010) Jorrit M Enserink et al. Cell Division
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
- (2009) Antonio Jimeno et al. JOURNAL OF CLINICAL ONCOLOGY
- RNA interference screening demystified
- (2009) C J Lord et al. JOURNAL OF CLINICAL PATHOLOGY
- AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
- (2009) K. F. Byth et al. MOLECULAR CANCER THERAPEUTICS
- Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
- (2009) M. S. Squires et al. MOLECULAR CANCER THERAPEUTICS
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- Ras oncogenes: split personalities
- (2008) Antoine E. Karnoub et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
- (2008) F. Di Nicolantonio et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A chemical method for fast and sensitive detection of DNA synthesis in vivo
- (2008) A. Salic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started